Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study assessing the safety and immunogenicity of two doses of a novel H5 central antigen mRNA-LNP vaccine in heal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Avian Influenza

Drugs mentioned

• H5 Central Antigen mRNA-LNP

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Avian Influenza | Phase 1 | Status: ACTIVE_NOT_RECRUITING